Health-related quality of life with zanubrutinib versus ibrutinib for patients with R/R CLL

Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, shares some insights into patient-reported health-related quality of life (HRQOL) with the use of zanubrutinib versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Eichhorst discusses the EORTC-QLQ-C30 questionnaire used in this study and further highlights the results obtained. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.